Should You Take Aspirin Every Day? Here ’s What the Science Says

Aspirin is best known as an over-the-counter painkiller. But acetylsalicylic acid, as it’s called chemically, has many other health benefits, as well as side effects, in the body that have only become clear in recent years. Here’s what the latest science says about the health benefits and side effects of aspirin, as well as which conditions it may treat and those it doesn’t appear to improve. (If you are taking aspirin for any reason other than for periodic pain relief, it’s best to consult with your doctor to confirm whether the benefits outweigh the risks in your particular case.) How aspirin affects heart health Aspirin’s second-best known effect is its ability to protect the heart. In people with heart disease who have already had a heart attack, it has been shown to lower the risk of having another. Studies consistently show that people who have had heart attacks or strokes and who take a low-dose aspirin (also known as baby aspirin, which at 81 mg is about a quarter of the dose of regular-strength aspirin) a day can significantly reduce their risk of having another event. Its protective benefits come from aspirin’s ability to lower inflammation, a condition that can attract clot-building factors within blood vessel walls. These can rupture, plugging up tiny vessels in the heart and blocking blood flow. Doctors now believe that taking a daily low-dose aspirin is also a cheap and easy way for people who do not yet have heart disease &m...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Drugs healthytime Source Type: news

Related Links:

Authors: Brignardello-Petersen R PMID: 30658722 [PubMed - as supplied by publisher]
Source: Journal of the American Dental Association - Category: Dentistry Tags: J Am Dent Assoc Source Type: research
Authors: PMID: 30659135 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Chen YJ PMID: 30659134 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Dyer BA, Zamarin D, Eskandar RN, Mayadev JM Abstract Despite combined therapeutic approaches, there is an unmet clinical need to identify effective strategies for improved patient outcomes in treating locally advanced and metastatic cervical cancer (CC). Immunotherapy is emerging as a novel therapeutic approach in this disease for which the causative agent, human papillomavirus (HPV), has dynamic, complex immunomodulatory effects. This review explores the biologic rational of immuno-oncology in the treatment of CC and discusses the initial clinical efficacy, ongoing clinical trials, and rationale for combi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Pennington KP, Urban RR, Gray HJ Abstract Minimally invasive surgery (MIS) was previously considered an acceptable alternative to open radical hysterectomy in the management of early-stage cervical cancer (ESCC), but adequately powered, high-quality prospective trials evaluating survival outcomes were lacking. Recently, a large randomized phase III trial, the Laparoscopic Approach to Cervical Cancer (LACC) trial, showed that MIS for ESCC is associated with a higher risk of recurrence and death compared with open surgery. We review the LACC trial findings in depth, as well as a recent National Cancer Databa...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL Abstract Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment of precancerous lesions. However, due to inadequate...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusions: This systematic review shows that E-DATs are feasible to implement in cancer survivors. Future research should examine the optimal type, dose, and schedule of E-DATs for cancer survivors. PMID: 30659130 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusions: Survival rates of patients with HER2+ breast cancer in our study are comparable to those seen in clinical trials. Our findings support chemotherapy de-escalation in patients with node-negative disease and validate the efficacy of FEC-DH in those with node-positive disease. PMID: 30659129 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP Abstract Background: Literature suggests that Oncotype DX (ODX) is cost-effective. These studies, however, tend to ignore clinical characteristics and have not incorporated population-based data regarding the distribution of ODX results across different clinical risk groups. Accordingly, this study assessed the cost-effectiveness of ODX across strata of clinical risk groups using population-based ODX data. Methods: We created state-transition models to calculate costs and quality-adjusted life years (QALYs) gained over the lifetime for women with es...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Wang Y, Yu X, Zhao N, Wang J, Lin C, Izaguirre EW, Farmer M, Tian G, Somer B, Dubal N, Schwartz DL, Ballo MT, VanderWalde NA Abstract Background: Chemotherapy with or without pelvic radiotherapy (RT) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for metastatic anal cancer (MAC), despite limited clinical evidence for RT in this setting. In addition, increasing evidence shows that local therapies, including RT, may increase patient survival for some types of metastatic cancers. The purpose of this study was to evaluate the patterns of care and association between definiti...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Acetaminophen | Alzheimer's | Arthritis | Aspirin | Australia Health | Babies | Babies Heart Conditions | Bleeding | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Chemistry | Cholesterol | Chronic Pain | Cirrhosis | Colon Cancer | Colorectal Cancer | Dementia | Diabetes | Diabetes Type 1 | Diabetes Type 2 | Disability | Eating Disorders & Weight Management | Endocrinology | Gastric (Stomach) Cancer | Gastroenterology | Government | Health | Heart | Heart Attack | Heart Disease | Hospitals | Hypertension | Ibuprofen | Italy Health | Learning | Liver | Liver Disease | Lortab | Neurology | Nurses | Nursing | Obesity | Ovarian Cancer | Ovaries | Pain | Rheumatology | Science | Smokers | Stroke | Study | Universities & Medical Training | Urology & Nephrology | Women